- €130 million investment in Molsheim, France, to expand single-use assembly production
- Creation of over 800 jobs by the end of 2028
- 3,500-square-meter ISO7 clean rooms operational by end of 2024
- Part of Merck's plan to reach €25 billion in sales by 2025
Investment and Expansion
Merck is investing over €130 million to enhance its manufacturing capabilities in Molsheim, France. This investment, the largest in the site's 50-year history, aims to increase the production capacity for single-use assemblies, crucial for Covid-19 vaccines and other therapies. The expansion will create more than 800 jobs by the end of 2028.
Infrastructure Development
The project includes the construction of 3,500-square-meter ISO7 clean rooms, an administrative building, and a new logistics warehouse. These facilities are expected to be operational by the end of 2024, with full production ramping up through 2028. This follows a previous €25 million investment in 2021 for a single-use assembly production unit at the same site.
Global Strategy
This expansion is part of Merck's broader strategy to increase its global manufacturing footprint and support the growing demand for biopharmaceutical products. The company aims to boost its Group sales to approximately €25 billion by 2025. To achieve this, Merck plans significant investments between 2021 and 2025, targeting countries like Germany, France, Switzerland, Ireland, China, and the USA.
Sustainability Goals
All expansion projects include clear targets for water consumption, waste management, and energy efficiency, aligning with Merck's goal to be climate neutral by 2040. Recent expansion projects have been announced in various locations, including the USA, Ireland, China, Germany, and Switzerland, as part of a multi-year program to enhance the industrial capacity of Merck’s Life Science business sector.
